Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 15/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820641 | 0.80 | MEN1 (0.57) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL12368141 | 0.78 | TYMS (0.46) | TYMSXDHKDM4EALDH1A1LMNA | |
| SCHEMBL10007309 | 0.76 | KDM4E (0.49) | TYMSKDM4EALDH1A1LMNAGLA | |
| SCHEMBL12393162 | 0.75 | KDM4E (0.49) | TYMSXDHKDM4EALDH1A1LMNA | |
| SCHEMBL12320826 | 0.72 | MAPT (0.44) | TYMSXDHKDM4EALDH1A1LMNA | |
| SCHEMBL7515343 | 0.71 | TYMS (0.42) | TYMSXDHLMNAMEN1MAPT | |
| SCHEMBL160586 | 0.70 | ALDH1A1 (0.53) | XDHKDM4EALDH1A1LMNAGLA | |
| SCHEMBL12820579 | 0.70 | HTT (0.46) | XDHKDM4EALDH1A1LMNAGLA | |
| 8-Aminoguanine SCHEMBL21760 | 0.69 | KDM4E (0.60) | TYMSKDM4EALDH1A1LMNAGLA | |
| SCHEMBL29819457 | 0.69 | KDM4E (0.51) | XDHKDM4EALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210826-A1 | METHODS FOR TREATING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110207753-A1 | METHODS FOR TREATING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| US-7906520-B2 | Reducing expression of tetrahydrobiopterin (BH4) biological activity; traumatic, metabolic or toxic peripheral nerve lesions | THE GENERAL HOSPITAL CORPORATION (US) | 2011-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210826-A1 | METHODS FOR TREATING PAIN | SPR, QDPR, SHMT1 | TYMS 686/4885XDH 2496/4885KDM4E 1344/4885 |
| US-20110207753-A1 | METHODS FOR TREATING PAIN | SPR, QDPR, SHMT1 | TYMS 722/4885XDH 1595/4885KDM4E 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.